FXCM Pro Announces Liquidity Bridging Partnership With Tools for Brokers
5.9.2023 11:00:00 EEST | Business Wire | Press release
FXCM Pro, the institutional arm of FXCM, a leading international provider of online foreign exchange trading, CFD trading and related services has announced a liquidity bridging partnership with Tools for Brokers (TFB), an international technology provider for retail brokers, prop trading companies, and hedge funds.
FXCM Pro will be streaming its institutional liquidity directly to TFB clients, enabling them to connect pricing and trading to their MT4 and MT5 platforms using TFB’s FIX API server. With this new partnership, FXCM Pro’s clients will benefit from having an additional option when selecting a technology/bridge provider.
TFB’s Trade Processor bridge works with the MT4 and MT5, cTrader, Match-Trader, and other platforms and supports third-party integrations via external FIX API. Additionally, it provides brokers with data analysis and enhanced risk management, all through a simple, user-friendly interface.
Mario Sanchez, Managing Director and Global Head of FXCM Pro Sales, commented: “At FXCM Pro, we are committed to providing our clients with the technology they need to succeed, and this is demonstrated in our partnership with Tools for Brokers. This collaboration gives our clients additional choice when it comes to selecting a bridging provider and by selecting TFB, they will benefit from fast execution, automation and improved market access.”
Alexey Kutsenko, CEO at Tools for Brokers, said, “We are excited to partner with FXCM Pro. Under the partnership, FXCM Pro’s clients will benefit from advanced and fast execution without compromising quality or security. Combining our experience and expertise will create a strong platform for many brokerages and hedge funds, allowing them to scale faster and more sustainably.”
FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime. Its relationships with tier 1 banks and non-bank liquidity providers, prime broker relationships and technology vendors provide clients with best-in-class market access.
Tools for Brokers (TFB) is an international technology provider for retail brokers, prop trading companies, and hedge funds operating on multiple platforms, including MetaTrader, Match-Trader, and cTrader. It offers an ecosystem of solutions centred around the flagship Trade Processor liquidity bridge, supported by data management and reporting, money management, and a single web-user interface for individual solutions’ management.
For more information on FXCM, please visit http://www.fxcm.com/
For more information on TFB, please visit https://t4b.com/
###
Disclaimers:
This communication is intended for institutional and professional clients only.
About FXCM:
FXCM is a leading provider of online foreign exchange (FX) trading, CFD trading, and related services. Founded in 1999, the company's mission is to provide global traders with access to the world's largest and most liquid market by offering innovative trading tools, hiring excellent trading educators, meeting strict financial standards, and striving for the best online trading experience in the market. Clients have the advantage of mobile trading, one-click order execution and trading from real-time charts. In addition, FXCM offers educational courses on FX trading and provides trading tools, proprietary data and premium resources. FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime.
About Tools for Brokers:
Tools for Brokers (TFB) is a multiplatform technology provider for retail brokers, prop trading companies, and hedge funds with solutions operating on MetaTrader, Match-Trader, and cTrader. The ecosystem of products centers around the Trade Processor liquidity bridge, enhanced with data management and reporting functionality, TFB PAMM for money management, and the TFB Toolbox — a single web-user interface for individual custom solutions’ management. The flagship multiplatform liquidity bridge solution — Trade Processor — supports a pool of liquidity providers, helps clients manage risks, collects data, and automates the most critical processes all through a single console.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905624094/en/
Contact information
FXCM Media contact:
Chatsworth Communications
+44 (0) 20 7440 9780
fxcm@chatsworthcommunications.com
Tools for Brokers contact:
Yulia Ogorodnikova
y.ogorodnikova@t4b.com
Tel: +447503599088
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom